JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kest, B.
Right arrow Articles by Inturrisi, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kest, B.
Right arrow Articles by Inturrisi, C. E.

Vol. 283, Issue 3, 1249-1255, 1997

The Competitive alpha -Amino-3-Hydroxy-5-Methylisoxazole-4-Propionate Receptor Antagonist LY293558 Attenuates and Reverses Analgesic Tolerance to Morphine But Not to Delta or Kappa Opioids1

Benjamin Kest, Gabrielle McLemore, Bernard Kao and Charles E. Inturrisi

Department of Pharmacology, Cornell University Medical College, New York, New York

Antagonists of the NMDA type of excitatory amino acid (EAA) receptor attenuate or reverse the development of tolerance to the analgesic effects of the mu opioid agonist morphine, the delta-1 opioid agonist DPDPE but not the kappa-1 agonist U50,488H or the kappa-3 agonist naloxone benzoylhydrazone. The role of the AMPA subtype of EAA receptor in analgesic tolerance was examined using LY293558, a selective competitive antagonist that is active after systemic administration. Administration of morphine, DPDPE, or U50,488H three times daily for 3 days according to an escalating dosing schedule resulted in analgesic tolerance as indicated by an increase in analgesic ED50 values using the tail-flick test in mice. Analgesic tolerance was attenuated when mice received a continuous subcutaneous infusion of LY293558 at doses of 30, 45 or 60 mg/kg/24 hr via an osmotic pump concurrent with the morphine treatment. Continuous subcutaneous infusion of LY293558 (45 mg/kg/24 hr) also reversed established morphine tolerance. In contrast, continuous subcutaneous infusion of the highest dose of LY293558 (60 mg/kg/24 hr) was ineffective in preventing the development of analgesic tolerance to DPDPE or U50,488H. Continuous subcutaneous infusion of LY293558 (60 mg/kg/24 hr) for 3 days protected mice from generalized convulsions produced by the selective AMPA agonist ATPA, indicating that the dosage of LY293558 that attenuated morphine tolerance was effective as an antagonist at AMPA receptors. These results demonstrate that AMPA receptors may play a role in the development and maintenance of morphine, but not DPDPE or U50,488H, analgesic tolerance.

0022-3565/97/2833-1249$03.00/0
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. J. Bogulavsky, A. M. Gregus, P. T.-H. Kim, A. C. S. Costa, A. M. Rajadhyaksha, and C. E. Inturrisi
Deletion of the Glutamate Receptor 5 Subunit of Kainate Receptors Affects the Development of Morphine Tolerance
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 579 - 587.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. M. Garraway, Q. Xu, and C. E. Inturrisi
Design and Evaluation of Small Interfering RNAs That Target Expression of the N-Methyl-D-aspartate Receptor NR1 Subunit Gene in the Spinal Cord Dorsal Horn
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 982 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. C. Van Elstraete, P. Sitbon, F. Trabold, J.-X. Mazoit, and D. Benhamou
A Single Dose of Intrathecal Morphine in Rats Induces Long-Lasting Hyperalgesia: The Protective Effect of Prior Administration of Ketamine
Anesth. Analg., December 1, 2005; 101(6): 1750 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. Hansen, I. Gilron, and M. Hong
The Effects of Intrathecal Gabapentin on Spinal Morphine Tolerance in the Rat Tail-Flick and Paw Pressure Tests
Anesth. Analg., October 1, 2004; 99(4): 1180 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
O. Y. Vekovischeva, D. Zamanillo, O. Echenko, T. Seppala, M. Uusi-Oukari, A. Honkanen, P. H. Seeburg, R. Sprengel, and E. R. Korpi
Morphine-Induced Dependence and Sensitization Are Altered in Mice Deficient in AMPA-Type Glutamate Receptor-A Subunits
J. Neurosci., June 15, 2001; 21(12): 4451 - 4459.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. Martin, S. H. Ahmed, T. Blank, J. Spiess, G. F. Koob, and G. R. Siggins
Chronic Morphine Treatment Alters NMDA Receptor-Mediated Synaptic Transmission in the Nucleus Accumbens
J. Neurosci., October 15, 1999; 19(20): 9081 - 9089.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.